Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 33048366.
- Also identified by DOI 10.1002/cncr.33220 and PMC identifier 7756288.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article describes a case of metastatic, bulky, high‐grade, rapidly progressive myoepithelial carcinoma with <i>EWSR1‐POU5F1</i> fusion originating from the left kidney that demonstrated a dramatic, deep response within 2 cycles of treatment with a regimen used for patients with Ewing sarcoma and an ongoing sustained response of >10 months. To the author's knowledge, this is the first report of a rapid and deep response using a systemic therapy regimen in a patient with myoepithelial carcinoma with <i>EWSR1‐POU5F1</i> fusion.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Liver Neoplasms
- Myoepithelioma
- Octamer Transcription Factor-3
- RNA-Binding Protein EWS